search
Back to results

Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment

Primary Purpose

Henoch-Schönlein Purpura Nephritis

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Glycosides Of Tripterygium Wilfordii Hook(GTW)
Sulfotanshinone Sodium Injection
Chinese herbs based on syndrome differentiation
Prednisone Acetate Tablets
Benazepril Hydrochloride Tablets
Low Molecular Weight Heparin Calcium Injection
Dipyridamole Tab 25 MG
Chinese medicine placebo
Sponsored by
Henan University of Traditional Chinese Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Henoch-Schönlein Purpura Nephritis focused on measuring Children,, Henoch-Schönlein Purpura Nephritis, Integrated and Stepped Treatment in TCM

Eligibility Criteria

2 Years - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Clinical diagnosis of Henoch-Schönlein Purpura Nephritis Disease
  • Age form 2-18 years old
  • Disease onset within 2 months

Exclusion Criteria:

  • Nephritis not causing by HSPN
  • Being alergic to the medicine in the treatment
  • No compliance

Sites / Locations

  • Children's Hospital, The First Affiliated Hospital of HUTCMRecruiting
  • The First Affiliated Hospital of Henan University of Traditional Chinese MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

TCM multistep therapy

Routine medicine

Arm Description

Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total. On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time.

Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks. Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued(Reduce the dosage at the rate of 5mg every other day in 4-8 weeks,then reduce the dosage at the rate of 5-10mg per week in 8-12weeks)

Outcomes

Primary Outcome Measures

24-hour urinary protein quantity
24-hour urinary protein is the most important and direct indicators of therapeutic effect,so this clinical lab index should be reccord at every point during treatment and follow-up,17 times in total.

Secondary Outcome Measures

Urine red blood cells
Compared to 24-hour urinary protein,urine red blood cells count is a secondary indicator to reflect therapeutic effect because urine red blood cells recede more slowly than protein,this clinical lab index should also be reccorded at every point during treatment and follow-up,17 times in total.

Full Information

First Posted
December 9, 2014
Last Updated
July 7, 2018
Sponsor
Henan University of Traditional Chinese Medicine
Collaborators
Peking University First Hospital, Children's Hospital of Fudan University, Shanghai Children's Hospital, Chengdu University of Traditional Chinese Medicine, Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT03591471
Brief Title
Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment
Official Title
Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 2014 (Actual)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Henan University of Traditional Chinese Medicine
Collaborators
Peking University First Hospital, Children's Hospital of Fudan University, Shanghai Children's Hospital, Chengdu University of Traditional Chinese Medicine, Affiliated Hospital of Yunnan University of Traditional Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the optimum dosage and application method of Glycosides Of Tripterygium Wilfordii Hook(GTW) for Henoch-Schönlein Purpura Nephritis(HSPN) in children, and develop into the normal treatment protocols for Henoch-Schönlein Purpura Nephritis in children.
Detailed Description
Based on Chinese Eleventh Five-year Plan for Science and Technology Program, this study follows a large-sample multicenter centerrandom open-label controlled perspective method, enrolls HSPN children with hematuria associated with proteinuria and isolated proteinuria from 2 to 18 years of age, classifys five traditional Chinese medicine patterns of syndrome: wind-heat complicated with blood stasis, blood-heat complicated with blood stasis, yin deficiency complicated with blood stasis, both qi and yin deficiency complicated with blood stasis,damp-heat complicated with blood stasis. For TCM group,according to the severity of HSPN, stepped treatment should be taken. The initial dosage of GTW for severe HSPN is 2mg/kg/d, continued with 1.5mg/kg/d and 1mg/kg/d; The initial dosage of GTW for light HSPN is 1.5mg/kg/d, continued with 1mg/kg/d. On the above base, the comprehensive treatment are taken combined with TCM syndrome differentiation, medicated with Sulfotanshinone Sodium Injection.For controlled group,the treatment for severe HSPN is prednisone combined with heparin plus lotensin and dipyridamole tablets;for light HSPN is heparin plus lotensin and dipyridamole tablets.12 weeks after treatment, the third-party statistics evaluate the efficacy and effect,and a follow-up lasting 36 weeks will go on.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Henoch-Schönlein Purpura Nephritis
Keywords
Children,, Henoch-Schönlein Purpura Nephritis, Integrated and Stepped Treatment in TCM

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TCM multistep therapy
Arm Type
Experimental
Arm Description
Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total. On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time.
Arm Title
Routine medicine
Arm Type
Active Comparator
Arm Description
Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks. Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued(Reduce the dosage at the rate of 5mg every other day in 4-8 weeks,then reduce the dosage at the rate of 5-10mg per week in 8-12weeks)
Intervention Type
Drug
Intervention Name(s)
Glycosides Of Tripterygium Wilfordii Hook(GTW)
Intervention Description
For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks. Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time
Intervention Type
Drug
Intervention Name(s)
Sulfotanshinone Sodium Injection
Intervention Description
Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
Intervention Type
Drug
Intervention Name(s)
Chinese herbs based on syndrome differentiation
Intervention Description
For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis "Blood Stasis": based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome.
Intervention Type
Drug
Intervention Name(s)
Prednisone Acetate Tablets
Intervention Description
Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued(Reduce the dosage at the rate of 5mg every other day in 4-8 weeks,then reduce the dosage at the rate of 5-10mg per week in 8-12weeks)
Intervention Type
Drug
Intervention Name(s)
Benazepril Hydrochloride Tablets
Other Intervention Name(s)
Lotensin
Intervention Description
In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
Intervention Type
Drug
Intervention Name(s)
Low Molecular Weight Heparin Calcium Injection
Intervention Description
In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
Intervention Type
Drug
Intervention Name(s)
Dipyridamole Tab 25 MG
Other Intervention Name(s)
Persantine
Intervention Description
In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
Intervention Type
Drug
Intervention Name(s)
Chinese medicine placebo
Intervention Description
In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
Primary Outcome Measure Information:
Title
24-hour urinary protein quantity
Description
24-hour urinary protein is the most important and direct indicators of therapeutic effect,so this clinical lab index should be reccord at every point during treatment and follow-up,17 times in total.
Time Frame
Changes in the quantity of urinary protein at week 1、week2、week 4、week6、week8、week10 and week12 of the treatment phase and at week16、week20、week24、week28、week32、week36、week40、week44、week48 of the follow-up phase compared with baseline
Secondary Outcome Measure Information:
Title
Urine red blood cells
Description
Compared to 24-hour urinary protein,urine red blood cells count is a secondary indicator to reflect therapeutic effect because urine red blood cells recede more slowly than protein,this clinical lab index should also be reccorded at every point during treatment and follow-up,17 times in total.
Time Frame
Changes in the quantity of urinary protein at week 1、week2、week 4、week6、week8、week10 and week12 of the treatment phase and at week16、week20、week24、week28、week32、week36、week40、week44、week48 of the follow-up phase compared with baseline
Other Pre-specified Outcome Measures:
Title
The white blood cell count(WBC) in the blood
Description
There is a potential risk of abnormality in the blood system in terms of leukocyte counts after taking immunosuppressor or prednison. Leukocyte count should be recorded in total of 17 times during and after treatment through routine blood tests.
Time Frame
Week0(before treatment),week1、week2、week4、week6、week8、week10 and week12 of the treatment phase and week16、week20、week24、week28、week32、week36、week40、week44、week48 of the follow-up phase
Title
The platelet count(PLT) in the blood
Description
There is a potential risk of abnormality in the blood system in terms of platelet counts after taking immunosuppressor or prednison. Platelet count should be recorded in total of 17 times during and after treatment through routine blood tests.
Time Frame
Week0(before treatment),week1、week2、week4、week6、week8、week10 and week12 of the treatment phase and week16、week20、week24、week28、week32、week36、week40、week44、week48 of the follow-up phase
Title
Glutamate alanine transferase(ALT) in the blood
Description
There is a potential risk of dysfunction in liver after using any drug. As one of the indicators of liver damage,the test of ALT should be taken in total of 11 times during and after treatment through a liver function test by taking blood from vein.
Time Frame
Week0(before treatment),week1、week2、week4、week8、week12 of the treatment phase and week20、week28、week36、week44、week48 of the follow-up phase
Title
Glutamate aspartate transferase(AST) in the blood
Description
There is a potential risk of dysfunction in liver after using any drug. As one of the indicators of liver damage,the test of AST should be taken in total of 11 times during and after treatment through a liver function test by taking blood from vein.
Time Frame
Week0(before treatment),week1、week2、week4、week8、week12 of the treatment phase and week20、week28、week36、week44、week48 of the follow-up phase
Title
Serum Creatinine(Scr)
Description
There is a potential risk of dysfunction in kidney after using any drug. As an indicator of kidney damage,the test of Cr should be taken in total of 11 times during and after treatment through a kidney function test by taking blood from vein.
Time Frame
Week0(before treatment),week1、week2、week4、week8、week12 of the treatment phase and week20、week28、week36、week44、week48 of the follow-up phase
Title
Blood Urea Nitrogen(BUN)
Description
There is a potential risk of dysfunction in kidney after using any drug. As an indicator of kidney damage,the test of BUN should be taken in total of 11 times during and after treatment through a kidney function test by taking blood from vein.
Time Frame
Week0(before treatment),week1、week2、week4、week8、week12 of the treatment phase and week20、week28、week36、week44、week48 of the follow-up phase

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of Henoch-Schönlein Purpura Nephritis Disease Age form 2-18 years old Disease onset within 2 months Exclusion Criteria: Nephritis not causing by HSPN Being alergic to the medicine in the treatment No compliance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ying Ding, professor
Phone
+86-371-66221361
Email
dingying3236@sina.com
First Name & Middle Initial & Last Name or Official Title & Degree
Guizhen Zheng, Lecturer
Phone
+86-371-65962457
Email
zhengguizhen@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ying Ding, professor
Organizational Affiliation
Henan University of Traditonal Chinese Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital, The First Affiliated Hospital of HUTCM
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Ding, Director
Phone
+86-13503840642
Email
dingying3236@sina.com
First Name & Middle Initial & Last Name & Degree
Xia Zhang, secretary
Phone
+86-13838276039
Email
zhangxia_125@163.com
First Name & Middle Initial & Last Name & Degree
Ying Ding, Director
Facility Name
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ying Ding, MD
Phone
+86-371-66221361
Email
dingying3236@sina.com
First Name & Middle Initial & Last Name & Degree
Xia zhang, MD
Phone
+86-371-13213210370
Email
ardar123@sina.com
First Name & Middle Initial & Last Name & Degree
Jiansheng Li, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
We allow all the data to be made public once the trial finished
IPD Sharing Time Frame
Our data will become availiable from January,2019 and for 10 years
Citations:
PubMed Identifier
31464626
Citation
Ding Y, Zhang X, Ren X, Zhai W, He L, Liu J, Yao C, Han S, Wang L. Traditional Chinese medicine versus regular therapy in Henoch-Schonlein purpura nephritis in children: study protocol for a randomized controlled trial. Trials. 2019 Aug 29;20(1):538. doi: 10.1186/s13063-019-3484-3.
Results Reference
derived

Learn more about this trial

Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment

We'll reach out to this number within 24 hrs